IMBRUVICA offers a wealth of experience for your CLL patients1-3,6,11

Find out more below

Early Use of Imbruvica

Imbruvica® first in the Relapsed/Refractory CLL treatment sequence can make for an efficacious treatment and provides meaningful patient benefits.1,3,4 Early use of Imbruvica® is supported by both published literature and real-world evidence.1,3-5

All Patients High-risk*

Find out more on the benefits of early use Imbruvica on the Janssen Medical Cloud


IMBRUVICA® offers a track record of experience that you can believe in.1-3,6,11

IMBRUVICA® has extensive clinical experience over 3 B-cell malignancies and real word evidence (RWE).1-3, 6-14

Find out more about Imbruvica's efficacy on the Janssen Medical Cloud

Tolerability - IMBRUVICA is generally well-tolerated over the long term

AEs are generally low Grade in the long term1,2,19

Incidence of most AEs (except hypertension) generally diminishes over time1-3,19

Dose adjustments and discontinuations due to AEs are infrequent and occur mostly in the first year of treatment1,2*

IMBRUVICA clinical trials have included a variety of CLL patients, with 5 CLL studies including high-risk patients such as those with del(17p) or del(11q)1-3, 7,9

Find out more on Imbruvica's tolerability profile on the Janssen Medical Cloud

Patient Benefits


Click here for Imbruvica patient materials on the Janssen Medical Cloud

Case Studies

Charles received IMBRUVICA 420 mg once daily

A year later, Charles is still on IMBRUVICA therapy and remains well

  • Platelet count monitored closely but improving with prophylaxis
  • No B symptoms
  • No lymph nodes palpable
  • No masses or organomegaly in abdomen

After 2 years of treatment with IMBRUVICA, Charles is continuing to feel well, with no B symptoms


Initially presented with CLL

  • Hb 15.4 g/L, WBC 32.4 x 109/L,
    Platelets 141 x 109/L
  • Persistent lymphocytosis over 2 months
  • ECOG: 0 with uncontrolled atrial fibrillation
  • Unmutated IGHV

Treatment approach: watch and wait

Treatment initiation

  • Hb 15.2 g/L, WBC 310 x 109/L,
    Platelets 126 x 109/L
  • Palpable splenomegaly
  • Lymphocyte doubling time <6 months
  • Weight loss >4 kg in less than 2 months

Treatment: 6 cycles FCR

  • Rituximab given at a reduced dose of 100 mg on day 1 and rest of treatment given on day 2 due to risk of tumour lysis.
    • Partial remission at treatment completion
  • Flutter ablation procedure
  • Hb 128 g/L, WBC 100.2 x 109/L,
    Platelets 148 x 109/L
  • Lymphocyte doubling time <6 months
  • FISH: ATM deletion present, P53 negative, del(17p) negative

Progressive disease with ATM mutation (5 years after treatment)


  • Previous atrial fibrillation with successful DC cardioversion
  • Hypertension

Find out more on Janssen Medical Cloud

Adverse events should be reported. Reporting forms and information can be found at or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Janssen-Cilag Limited on 01494 567447 or at


  1. Munir T, et al. Final analysis from RESONATE: up to 6 years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol 2019;94(12):1353-1363.
  2. Burger JA, et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 Study. Leukemia 2020; 34:787-798
  3. Byrd J.C. et al. 2020. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase 1b/2 PCYC-1102 Study. Clinical cancer research.2020; 26 (15) p.3918-3927
  4. Barr P, et al. Using Ibrutinib in Earlier Lines of Treatment Results in Better Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Poster Presented at the American Society of Hematology Annual Meeting (ASH) December 7–10, 2019; 134 (Suppl) p.3054-3054
  5. Follows G, et al. UK CLL Forum 5 year update on 315 relapsed refractory CLL patients treated with ibrutinib in 66 UK and Ireland centres. Abstract presented at the 61st ASH Annual Meeting & Exposition; 7−10 December 2019; Orange County Convention Center (OCCC), Orlando, FL, USA.
  6. Fraser et al. Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma, Leukemia & Lymphoma, 2020; DOI: 10.1080/10428194.2020.1795159
  7. O'Brien SM, et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol 2016;17(10):1409–1418.
  8. Woyach JA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Eng J Med 2018;379(26):2517–2528.
  9. Moreno C, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab as first-line treatment in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: up to 4 years of extended follow-up from the phase iLLUMINATE study. Poster presented at the XVIII International Workshop on CLL (iwCLL) Meeting; 20-23 September 2019;Edinburgh, Scotland. #2069.
  10. Rule S, et al. Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. Leukemia 2018;32(8):1799–1803.
  11. Rule S, et al. Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: Extended 3.5-year follow-up from a pooled analysis. Haematologica 2019;104(5):e211−e214.
  12. Treon SP, et al. Ibrutinib monotherapy produces long-term disease control in previously treated Waldenstrom's macroglobulinemia. Final report of the pivotal trial. Haem Onc 2019;37(S2):184–185.
  13. Buske C, et al. Ibrutinib treatment in Waldernström's macroglobulinemia: follow-up efficacy and safety from the iNNOVATETM study. Oral presentation at the 60th ASH Annual Meeting & Exposition; 1−4 December 2018; San Diego, CA, USA.
  14. IMBRUVICA® UK Summary of Product Characteristics. Janssen-Cilag Limited. August 2020
  15. Barr PM, et al. Final analysis from RESONATE: 6-year follow-up in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma on ibrutinib. Poster presented at the American Society of Clinical Oncology (ASCO) Annual Meeting; 31 May−4 June 2019 Chicago, IL, USA.
  16. Byrd JC, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014;371(3):213−223
  17. Jones JA, et al. Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib. Br J Haematol 2017; 178:286−291. (supplementary information).
  18. Dartigeas C, et al. French ibrutinib observational study (FIRE): real-world study of ibrutinib treatment for chronic lymphocytic leukemia (CLL) in France. HaemaSphere 2019;3:145−146
  19. O'Brien SM, et al. Safety analysis of four randomized controlled studies of ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma or mantle cell lymphoma. Clin Lymphoma Myeloma Leuk 2018;18(10:648–657.)
  20. Janssen Data on File. Ibrutinib - global number of cumulative patients treated with Ibrutinib since launch. July 2020
  21. Jain P, et al. Long-term outcomes for patients with chronic lymphocytic leukaemia who discontinue ibrutinib. Cancer 2017;15(123):2268–2273
  22. Mato AR, et al. Optimal sequencing of ibrutinib, idelalisib and venetoclax in CLL: Results from a large mutlicenter study of 683 US patients. Ann Oncol 2017;28(5):1050–1056 (Supplementary Appendix)
  23. Barrientos JC, et al. Improvement in parameters of hematologic and immunologic function and patient well-being in the phase III RESONATE study of ibrutinib versus ofatumumab in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma. Clin Lymphoma Myeloma Leuk 2018;18(12):803−813.e7.
  24. CLL Patient Voices Survey Final Report. Janssen. cll_patient_voices_survey_results_presenation_2018_05_13.pdf. Last Accessed October 2020.
Date of Preparation: December 2020 | CP-184726